Medanta to Commence IPD Services in Patna Hospital
Global Health Limited, one of the largest private multi-speciality tertiary care providers operating in the North and East regions of India with key specialties of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urology (Source: Based on the report titled “An assessment of the healthcare delivery market in India”, September 2021 prepared and released by CRISIL Limited) today announced the commencement of their in-patient (IPD) services at Jay Prabha Medanta Super Specialty Hospital in Patna.
Shri Nitish Kumar, Chief Minister, Bihar and Dr. Naresh Trehan, Chairman and Managing Director, Medanta during the ribbon cutting ceremony to launch the Jay Prabha Medanta hospital in Patna
In-line with its commitment to clinical excellence and patient care, Jay Prabha Medanta Super Specialty Hospital in Patna under its “Medanta” brand shall complement the flagship Medanta Hospital at Gurugram in the New Delhi National Capital region.
Commenting on the occasion, Hon’ble Chief Minister, Shri Nitish Kumar Ji said, “I am delighted to dedicate quality healthcare to citizens of Bihar through Jay Prabha Medanta Super Specialty Hospital. The hospital will offer technologically advanced treatment, and be a new benchmark of healthcare in the state.”
The hospital will offer doctor-driven, multi-disciplinary approach to treatment across: cardiology & cardiac surgery, neurology & neurosurgery, gastroenterology & hepatology*, gastro surgery, urology & nephrology, orthopaedics & joint replacement, gynaecology*, radiology, respiratory medicine, internal medicine, diabetes & endocrinology, dental sciences*, critical care & anaesthesiology and radiology.
Jay Prabha Medanta Super Specialty Hospital has a gross area size of approximately 1.0 million sq. ft., is spread across 7 acres and is designed to accommodate 500 beds#, 112 critical care beds# and 14 operating theatres#. It is expected to have 300 installed beds by Fiscal 2022.
Dr. Naresh Trehan, Chairman & Managing Director, Medanta said, “At Medanta, we strive to deliver world-class healthcare by establishing institutes of excellence that integrate medical care, teaching and research all while providing affordable medical services to patients. We also equip our hospitals with advanced medical technology and equipment, and diagnostic instruments with the aim of providing our patients with accurate diagnoses and effective treatments. With the commencement of the IPD facility at our Patna hospital, we intend to address what we expect to be a sizeable healthcare demand from North East India, parts of Jharkhand and Nepal.”
*Execution in progress
Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third and fourth-highest civilian awards in India and B C Roy award in recognition of his distinguished contribution to medicine, Global Health Limited (the “Company”) is one of the largest private multi-speciality tertiary care providers operating in the North and East regions of India, with key specialties of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urology, according to the report titled “An assessment of the healthcare delivery market in India, September 2021
Under the “Medanta” brand, the Company has a network of four hospitals currently in operation (Gurugram, Indore, Ranchi and Lucknow). Spanning an area of 3.7 million sq. ft., its operational hospitals have 2,176 installed beds as at March 31, 2021. It is now commencing in-patient operations at Patna and also has one hospital planned for development in Noida. As at March 31, 2021, the Company provides healthcare services in over 30 medical specialties and engages over 1,100 doctors led by highly experienced department heads.
The Company’s facilities have received national and international accreditations, including the NABH accreditation for the hospital and blood bank at Gurugram. The Gurugram hospital was ranked as the best private hospital in India for two consecutive years in 2020 and 2021, and was the only Indian private hospital to be featured in the list of top 200 global hospitals in 2021 by Newsweek. The Gurugram hospital was also featured in the list of world’s best specialized hospitals for cardiology in 2021, and cardiology and neurology in 2022 rankings released by Newsweek.
Certain Information in this letter is from the report titled “An assessment of the healthcare delivery market in India, September 2021” by CRISIL Limited, which is subject to the following disclaimer:
CRISIL Research, a division of CRISIL Limited (CRISIL) has taken due care and caution in preparing this report (Report) based on the Information obtained by CRISIL from sources which it considers reliable (Data). CRISIL does not guarantee the accuracy, adequacy or completeness of any material contained in or referred to in the Report. This Report is not a recommendation to invest/disinvest in any entity covered in the Report and no part of this Report should be construed as an expert advice or investment advice or any form of investment banking within the meaning of any law or regulation. CRISIL especially states that it has no liability whatsoever to the subscribers / users / transmitters/ distributors of this Report. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary permission and/or registration to carry out its business activities in this regard. Global Health Limited will be responsible for ensuring compliances and consequences of non-compliances for use of the Report or part thereof outside India. CRISIL Research operates independently of, and does not have access to information obtained by CRISIL Ratings Limited / CRISIL Risk and Infrastructure Solutions Ltd (CRIS), which may, in their regular operations, obtain information of a confidential nature. The views expressed in this Report are that of CRISIL Research and not of CRISIL Ratings Limited / CRIS. No part of this Report may be published/reproduced in any form without CRISIL’s prior written approval.